Vol 4, No 4 (2003): Practical Diabetology
Research paper
Published online: 2003-09-18
Effects of treatment with HM insulin produced by Bioton, NovoNordisk and Eli Lilly in children with type 1 diabetes diagnosed in 2001 and 2002
Diabetologia Praktyczna 2003;4(4):295-298.
Abstract
INTRODUCTION. The aim of the study was the appreciation of the degree of
metabolic control in children treated with Bioton, Novo Nordisk or Eli Lilly insulin.
MATERIAL AND METHODS. Examined were 142 children with type 1 diabetes treated in the years 2001 and 2002, aged 2–18 years (mean 11,5 years). Analyzed were age, duration of the diabetes therapy, frequency of acute complications, HbA1c.
RESULTS. The mean levels of HbA1c were in the group 1 - 7,28%, group 2 - 6,58%, group 3 - 7,64%. In the investigated children severe hypoglycemia was not observed. Only in the group of 6 youngest children (< 5 years of age) in the course of acute infections observed were metabolic ketosis. In all the children observed was a decrease of insulin requirement but in none of them a complete remission.
CONCLUSION. The treatment with insulin Bioton, Novo Nordisk and Eli Lilly restored a good metabolic control in patients with type 1 diabetes. Patients treated with an intensive insulin therapy with a pen for an optimalisation of the metabolic control should receive an intermediate insulin at least in two daily doses.
MATERIAL AND METHODS. Examined were 142 children with type 1 diabetes treated in the years 2001 and 2002, aged 2–18 years (mean 11,5 years). Analyzed were age, duration of the diabetes therapy, frequency of acute complications, HbA1c.
RESULTS. The mean levels of HbA1c were in the group 1 - 7,28%, group 2 - 6,58%, group 3 - 7,64%. In the investigated children severe hypoglycemia was not observed. Only in the group of 6 youngest children (< 5 years of age) in the course of acute infections observed were metabolic ketosis. In all the children observed was a decrease of insulin requirement but in none of them a complete remission.
CONCLUSION. The treatment with insulin Bioton, Novo Nordisk and Eli Lilly restored a good metabolic control in patients with type 1 diabetes. Patients treated with an intensive insulin therapy with a pen for an optimalisation of the metabolic control should receive an intermediate insulin at least in two daily doses.
Keywords: diabetes type 1insulin therapymetabolic control